Tarceva Survival Benefit Differentiates Oncologic From Iressa – Genentech

The survival benefit seen in Genentech/OSI's Tarceva non-small cell lung cancer monotherapy trial shows it is a "better product" than AstraZeneca's Iressa, Genentech maintained April 26

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet